Overview

A Study of ZT002 in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single ascending dose, sequential cohort design.
Phase:
Phase 1
Details
Lead Sponsor:
QL Biopharmaceutical Australia Pty Ltd
Collaborators:
Beijing QL Biopharmaceutical Co.,Ltd
Novotech (Australia) Pty Limited